MediPharm Labs Corp.
LABS.TO
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 36.96% | 11.98% | -17.31% | 47.26% | 46.92% |
| Total Depreciation and Amortization | -17.43% | 3.71% | 61.74% | 32.48% | -20.40% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 186.93% | 121.21% | 174.06% | -249.97% | -170.92% |
| Change in Net Operating Assets | -32.97% | 63.35% | -9.62% | 31.04% | -60.58% |
| Cash from Operations | 79.86% | 79.06% | 49.82% | 975.12% | -8.90% |
| Capital Expenditure | 87.51% | 18.04% | 15.68% | 61.56% | 19.98% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -29.51% | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -101.98% | -103.64% | 2,204.86% | -24.66% | 605.74% |
| Total Debt Issued | -- | -29.80% | -- | -- | -- |
| Total Debt Repaid | -490.72% | 81.27% | 35.18% | 27.32% | -40.07% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -77.53% | -89.42% | 140.28% | 7.91% | -33.58% |
| Cash from Financing | -630.87% | -38.36% | 92.79% | 39.76% | -103.38% |
| Foreign Exchange rate Adjustments | -81.56% | -75.83% | -- | -13.85% | -88.44% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -59.09% | 83.03% | 73.51% | 7.00% | 31.32% |
